Oct 13, 2017 04:34 PM IST
In an interview to CNBC-TV18, Rajesh Agrawal, CFO of Gulshan Polyols spoke about the latest happenings in the company and his outlook going ahead.
- Mar 25, 2015 07:18 PM IST
With Sun Pharma-Ranbaxy merger complete, Sun is now India's largest and the world's fifth largest drug maker with combined revenue of USD 5.14 billion
- Mar 24, 2015 03:29 PM IST
The company has 20 facilities across the globe with portfolio of more than 200 products in 138 countries.
- Dec 29, 2014 12:36 PM IST
As 2014 comes to an end, Surajit Pal of Prabhudas Lilladher shares his outlook on the year that was and the possible trends for 2015.
- Dec 09, 2014 10:59 AM IST
In an interview to CNBC-TV18, Ashok Chawla, Chairperson, CCI, said the order on Sun-Ranbaxy merger is final and that the companies could be given additional 4 months in case the product divestment process exceeds 6 months.
- Nov 07, 2014 10:14 AM IST
Ranbaxy has first-to-file status, meaning eligibility for six months of generic sales exclusivity for both AstraZeneca's heartburn drug Nexium & Roche's antiviral drug Valcyte drugs. However, the final approvals for these drugs were delayed because of the compliance issues at Ranbaxy's plants.
- Mar 14, 2014 12:27 PM IST
If a ban is imposed on the cholestoral drug, then Ranbaxy is likely to lose Rs 76 crore in revenues.
- Nov 27, 2013 05:07 PM IST
Drug-maker Wockhardt has fallen foul of the US drug regulator once again and this time, the focus is on its Chikalthana plant.
- Sep 16, 2013 11:16 AM IST
The question that needs to be resolved is what exactly is happening in terms of product filing and why is Ranbaxy saying that the product filings have not been impacted, says Vikas Dandekar, India Bureau Chief, PharmAsiaNews.Com.
- Sep 05, 2013 01:32 PM IST
Given the fact that US gets 35 percent of its drugs from India, the regulator is only doing its job in looking closely at not just India's, but other countries‘ pharma units too, adds Ramesh Adige, former executive director, Ranbaxy.
- Jul 13, 2013 04:38 PM IST
Ajay Piramal says that Indian growth will be higher than the rest of the world soon and adds that the financial services sector is ripe for investment with lucrative returns on offer.
- Jun 19, 2013 05:58 PM IST
Arun Sawhney, managing director and chief executive officer, Ranbaxy continues to deny any wrong doing. He says the USFDA's ban on its products is due to different definitions of what is 'adulterated' in the US and in India.
- Jun 12, 2013 02:16 PM IST
Agreeing to past misdeeds, Ranbaxy Laboratories says that the company is taking measure to set things right but cliams to be unaware of DCGI probe.
- May 29, 2013 04:38 PM IST
Ranbaxy shares declined a further 2 percent on Wednesday morning after a media report said a prominent hospital in Mumbai had advised doctors to stop using the pharma company's drugs.
- Apr 25, 2012 10:07 PM IST
Ranbaxy managing director and chief executive Arun Sawhney told CNBC-TV18 that the pharmaceutical company would end fiscal 2012 with better sales and profits
- Dec 01, 2011 08:56 AM IST
Vikas Dandekar of PharmAsiaNews.com tells CNBC-TV18 that the US FDA approval for Lipitor is definitely going to be a big positive for Ranbaxy.
- Nov 30, 2011 11:55 AM IST
Chirag Talati, pharma analyst at Espirito Santo Securities tells CNBC-TV18 that Ranbaxy is most likely set to go ahead with the launch of the generic version of Lipitor, but how much market share it commands needs to be watched.
- Mar 21, 2011 01:05 PM IST
The US Foods and Drugs Administration (USFDA) will be sued by the US pharmaceutical company Mylan Inc, for an injunction on the launch of Ranbaxy’s cholesterol treatment drug Aricept, which is a generic version of Pfizer’s Lipitor.
- Jan 27, 2011 08:26 AM IST
Ranbaxy CFO, Omesh Sethi has resigned. PharmAsia News India Bureau Chief, Vikas Dandekar, speaks exclusively to CNBC-TV18’s Reema Tendulkar on the exit and what it means for Ranbaxy.
- Jan 22, 2011 04:27 PM IST
Kamal Sharma, Managing Director of Lupin, started four decades ago almost as a stockiest and C&F agent. Today, his company is one of India’s largest drug manufacturers and the 5th largest generic drug manufacturer in the world.
- Jan 04, 2011 10:10 PM IST
Drug majors Ranbaxy and Merck have called off a deal that would have seen both the pharma giants join hands to research anti-infectives, reports PharmAsia News. The deal between the two companies was struck in 2008. Ranbaxy was to get milestones and an undisclosed upfront fee as part of the deal.